The global oncology drugs market is projected to grow at an 8-10% CAGR through 2035 as targeted therapies and immunotherapies gain share over chemotherapy. The radiopharmaceuticals market is expected to reach $21.8 billion by 2033, fueled by rising cancer incidence and expanding diagnostic and therapeutic applications. Innovations in drug delivery, including intranasal platforms for glioblastoma, are advancing neuro-oncology treatment options.
Global virus filters markets are projected for strong growth through 2035, with CAGRs of 7.2% to 8.2%, driven by expanding biologics production and stringent regulatory mandates for viral safety. Monoclonal antibody manufacturing remains the largest segment, while advanced therapy medicinal products are the fastest-growing area of demand.
Multiple market reports forecast the global biologics and antibody therapy markets will reach hundreds of billions of dollars by the 2030s, driven by monoclonal antibodies, biosimilar expansion, and targeted therapies.
Q4 earnings were mixed across 17 tracked pharmaceutical companies. Elanco and ANI Pharmaceuticals beat revenue estimates, while Corcept and Amphastar missed. The XPH pharma ETF posted a 29% one-year return but significantly lagged the S&P 500 over five and ten years.
The US pharmaceutical drug delivery market is projected to rise from USD 0.94 billion in 2026 to USD 1.24 billion by 2031 at a 5.8% CAGR. Injectables, oncology applications, and home care settings are expected to post the fastest growth.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
South Korea has approved fast-track drug listing for rare disease treatments, reducing the insurance coverage process from 240 days to 100 days. The reform includes post-listing effectiveness evaluations and flexible pricing agreements, aiming to improve patient access to innovative treatments amid ongoing budget concerns.
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
The FDA has eased biosimilar approval procedures as these therapies have generated $56 billion in savings since 2015. New guidance eliminates comparative efficacy studies, potentially saving manufacturers $100 million per product and cutting development time by 50%. Despite growth to 23% of the biologics market, a "biosimilar void" threatens $232 billion in missed savings over the next decade.
